Ocuphire Pharma, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Marketable Securities (Tables)

Marketable Securities (Tables)

12 Months Ended

Dec. 31, 2014

Schedule Of Cost And Fair Value Of Marketable Securities


			December 31, 2014
		Cost		Gross Unrealized		Gross Unrealized		Fair
		Basis		Gains		Losses		Value
Certificates of Deposit	$	18,865,000	$	60		(26,789)	$	18,838,271
Commercial Paper		1,998,001		62		(153)		1,997,910
Corporate Bonds		2,042,697		-		(6,827)		2,035,870
Total Marketable Securities	$	22,905,698	$	122	$	(33,769)	$	22,872,051

		December 31, 2013
		Cost		Gross Unrealized		Gross Unrealized		Fair
		Basis		Gains		Losses		Value
State and Municipal Obligations	$	100,000	$	-	$	-	$	100,000

Schedule Of Cost And Fair Value By Contractual Maturity


Maturity	Cost Basis		Fair Value
Less than 1 year	$	17,023,001	$	17,010,586
1 to 5 years		5,882,697		5,861,465
Total Marketable Securities	$	22,905,698	$	22,872,051

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

- Definition

Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.

+ References + Details